Physician profile
R Gregory Scheible
NPI 1194766840
$2,595.11
in general payments reported to CMS, 2019-2025
24 companies · $850 in 2025
The $850 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $52.45 · 2022: $45.03 · 2023: $405 · 2024: $1,009 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,203 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,202.88 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $614.72 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $411.57 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $248.49 | 2022-2025 | |
| Pfizer INC. | $206.22 | 2019-2025 | |
| Madrigal Pharmaceuticals | $131.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $115.01 | 2024-2025 | Omvoh |
| Janssen Biotech, INC. | $107.36 | 2023-2025 | Stelara, Tremfya |
| Celgene Corporation | $92.21 | 2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $80.56 | 2024-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $74.19 | 2024 | Iqirvo, Bylvay |
| Phathom Pharmaceuticals, INC. | $73.71 | 2024-2025 | Voquezna |
| Shionogi INC | $65.39 | 2019 | |
| Qol Medical, LLC | $52.10 | 2024 | Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.48 | 2019-2023 | Xifaxan |
| Aimmune Therapeutics, INC. | $46.91 | 2024-2025 | Vowst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $45.72 | 2024 | |
| Ironwood Pharmaceuticals, INC | $42.01 | 2023-2024 | Linzess |
| Biocon Biologics INC | $32.84 | 2024-2025 | Hulio, Yesintek |
| Romark Laboratories, Lc | $23.73 | 2019 | |
| Braintree Laboratories, INC. | $20.40 | 2023 | Sutab |
| Celltrion USA INC. | $19.14 | 2024 | Zymfentra |
| Amag Pharmaceuticals, INC. | $14.68 | 2019 | |
| Ardelyx, INC. | $14.16 | 2025 | Ibsrela |
| Allergan, INC. | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw R Gregory Scheible listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.